Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 18, Pages 2015-2040Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.12.068
Keywords
coronary artery disease; geriatric cardiology; octogenarians
Categories
Funding
- American Medical Association Foundation
- Gilead Sciences
- Sanofi
- GlaxoSmithKline
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Daiichi-Sankyo
- Janssen Pharmaceuticals
- Novartis Pharmaceutical Company
- Medtronic Foundation
- Pfizer
- U.S. Food and Drug Administration
- National Institutes of Health
- Boston Scientific
- Lilly
- Medtronic
- Merck
Ask authors/readers for more resources
Coronary artery disease (CAD) is a major cause of morbidity and mortality in patients >= 80 years of age. Nonetheless, older patients have typically been under-represented in cardiovascular clinical trials. Understanding the pathophysiology, epidemiology, and optimal means of diagnosis and treatment of CAD in older adults is crucial to improving outcomes in this high-risk population. A patient-centered approach, taking into account health status, functional ability and frailty, cognitive skills, and patient preferences is essential when caring for older adults with CAD. The present systematic review focuses on the current knowledge base, gaps in understanding, and directions for future investigation pertaining to CAD in patients >= 80years of age. (C) 2018 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available